Back to search
FDAFDA · Food and drugs·Recall number Z-2650-2026

Brilliance iCT Brilliance iCT Upgrades Brilliance iCT SP Brilliance CT 64 Channel CT6000 Brilliance 64 Upgrades

Published August 5, 2026 · Recall initiated: June 11, 2026

Summary

FDA records medical device Class II recall Z-2650-2026, published August 5, 2026 and initiated June 11, 2026. Recalling firm: PHILIPS MEDICAL SYSTEMS; Status: Ongoing; Reported quantity: 128; Lot: FCO72800812; FCO72800814 728305 728306 DI (01)00884838059474 728307 DI (01)00884838104600 728311 728231 (01)00884838083325 728232. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

The clinical CT scan may not automatically trigger after the Bolus Tracking scan and may need to be triggered manually. Additional Bolus Tracking shots may occur. This may result in the clinical acquisition being inadequate for diagnosis, causing a potential for patient rescan and receiving additional radiation.

What to do

FDA Mandated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
PHILIPS MEDICAL SYSTEMS
Distributor
US Nationwide Distribution including Puerto Rico
Lot
FCO72800812; FCO72800814 728305 728306 DI (01)00884838059474 728307 DI (01)00884838104600 728311 728231 (01)00884838083325 728232
Risk classification
Class II
Area (FDA)
device
Country
United States

Related recalls

Questions about this recall

Was Brilliance iCT Brilliance iCT Upgrades Brilliance iCT SP Brilliance CT 64 Channel CT6000 Brilliance 64 Upgrades recalled?

Yes. FDA published recall Z-2650-2026 on August 5, 2026. Reported hazard: The clinical CT scan may not automatically trigger after the Bolus Tracking scan and may need to be triggered manually. Additional Bolus Tracking shots may occur. This may result in the clinical acquisition being inadequate for diagnosis, causing a potential for patient rescan and receiving additional radiation.

What should I do if I have this product?

FDA Mandated · Letter